drugset / Trial / NCT02383888

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

NCT02383888

Phase 1 Completed 49 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety, tolerability and pharmacokinetics of BI 425809 tablets in healthy Chinese and Japanese male subjects following the administration of single rising oral doses and further to explore the pharmacokinetics (PK) including dose proportionality of BI 425809 after single dosing of product.

Timeline

Start
2015-05-11
Primary completion
2015-08-06
Completion
2015-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Iclepertin Small molecule 10 mg Oral
Subject Iclepertin Small molecule 25 mg Oral
Subject Iclepertin Small molecule 50 mg Oral

Indications

No indication recorded.